Endocrinology

The Connected MOM program allows self-monitoring during pregnancy so that some in-person visits can be skipped, and any issues can be identified early.

A new study of 55 million insured young adults in the US found that major depression, type 2 diabetes, and other conditions are becoming more prevalent among them.

“At first, I was afraid, I was petrified. I kept thinking I could never live without you by my side…” so the song goes. That is sort of how I felt when my associate told me she was leaving.

The TransPyloric Shuttle device is delivered endoscopically to the stomach and can be used for up to 12 months of treatment.

Drinking no water on a given day was associated with greater caloric intake overall and a greater percentage of calories coming from sweetened beverages.

Richard Milani, MD, shares about the digital medicine program, particularly the track for patients with hypertension.

Aimee Quirk, CEO of innovationOchsner shares about how they have improved aspects of health care by introducing uses of technology.

It's been nearly a century since one of the greatest medical findings reached patients. How has the story of insulin changed modern diabetes care?

To certify or not to certify, that is the question. There is no evidence that it improves patient care. And yet, the question often comes up in my discussions with colleagues:  Should we recertify? 

Is there an improved method of care for patients at risk of losing limbs?

The daily oral capsule was shown to reduce overweight and obese patient weight by about 6% over 6 months.

Additionally, the added sugar labels will save the health care system an estimated $31 billion.

The CREDENCE study of canagliflozin in adults with chronic kidney disease and type 2 diabetes met its primary endpoint as well as cardiovascular endpoints.

Time-restricted feeding has been shown in early trials to be a beneficial treatment for various cardiovascular disease risk metrics.

Are blood sugar levels moving targets? Should pregnant women be screened for thyroid cancer? And, will there soon be treatment to stave off those salt and sugar cravings? Learn more about these and other developments from endocrinology research in this news recap.

Primary care providers, endocrinologists and obstetricians have been challenged with the question of whether to screen all pregnant women for thyroid disease. The debate springs primarily from unknown clinical implications of subclinical thyroid disease during pregnancy. This issue was addressed at ENDO 2019.

The canagliflozin (Invokana) application seeks a new indication to treat chronic kidney disease in patients with type 2 diabetes.

The hormone oxytocin shows promise as a possible new treatment for obesity, according to research presented on Monday at ENDO 2019.

An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.

Over the course of 16 weeks, OSA patients receiving CPAP treatment lost 5.7 pounds more on average than patients not receving CPAP therapy.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

A new Puerto Rico-based trial shows that patients on add-on SGLT-2 inhibitors reported greater HbA1C reductions.

The FDA’s decision regarding sotagliflozin (Zynquista), an investigational treatment for type 1 diabetes, followed a split Advisory Committee vote in January.

With cardiovascular drug classes inhibitors owning discussion, how will recent or upcoming guideline updates address their use alongside lifestyle management?

The applications seek FDA approval for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes.